148 related articles for article (PubMed ID: 35254936)
1. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access.
Deverka PA; Douglas MP; Phillips KA
Health Aff (Millwood); 2022 Mar; 41(3):383-389. PubMed ID: 35254936
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy.
Trosman JR; Weldon CB; Kurian AW; Pasquinelli MM; Kircher SM; Martin N; Douglas MP; Phillips KA
Health Aff Sch; 2023 Jul; 1(1):qxad005. PubMed ID: 38756840
[TBL] [Abstract][Full Text] [Related]
3. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
Trosman JR; Weldon CB; Douglas MP; Kurian AW; Kelley RK; Deverka PA; Phillips KA
J Natl Compr Canc Netw; 2017 Feb; 15(2):219-228. PubMed ID: 28188191
[No Abstract] [Full Text] [Related]
4. Examining developments in multicancer early detection: highlights of new clinical data from recent conferences.
Beer TM
Am J Manag Care; 2021 Dec; 27(19 Suppl):S347-S355. PubMed ID: 34870399
[TBL] [Abstract][Full Text] [Related]
5. Testing Whether Cancer Screening Saves Lives: Implications for Randomized Clinical Trials of Multicancer Screening.
Welch HG; Dey T
JAMA Intern Med; 2023 Nov; 183(11):1255-1258. PubMed ID: 37639251
[TBL] [Abstract][Full Text] [Related]
6. Screening for cancer in low- and middle-income countries.
Sankaranarayanan R
Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
[TBL] [Abstract][Full Text] [Related]
7. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
8. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
Owens L; Gulati R; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1298-1304. PubMed ID: 35477176
[TBL] [Abstract][Full Text] [Related]
9. Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies.
Raoof S; Lee RJ; Jajoo K; Mancias JD; Rebbeck TR; Skates SJ
Cancer Epidemiol Biomarkers Prev; 2022 Jun; 31(6):1139-1145. PubMed ID: 35320352
[TBL] [Abstract][Full Text] [Related]
10. Considerations in the implementation of multicancer early detection tests.
Nadauld L; Goldman DP
Future Oncol; 2022 Sep; 18(28):3119-3124. PubMed ID: 36062430
[No Abstract] [Full Text] [Related]
11. Screening for cancer: the economic, medical, and psychosocial issues.
Brill JV
Am J Manag Care; 2020 Nov; 26(14 Suppl):S300-S306. PubMed ID: 33200894
[TBL] [Abstract][Full Text] [Related]
12. The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm.
Klein EA; Beer TM; Seiden M
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626398
[TBL] [Abstract][Full Text] [Related]
13. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies.
Doubeni CA; Lau YK; Lin JS; Pennello GA; Carlson RW
Cancer; 2022 Feb; 128 Suppl 4():883-891. PubMed ID: 35133658
[TBL] [Abstract][Full Text] [Related]
15. Medical students, clinical preventive services, and shared decision-making.
Keefe CW; Thompson ME; Noel MM
Acad Med; 2002 Nov; 77(11):1160-1. PubMed ID: 12431938
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. Mapping US commercial payers' coverage policies for medical interventions.
Chambers JD; Chenoweth MD; Neumann PJ
Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
[TBL] [Abstract][Full Text] [Related]
18. What women want: patient recommendations for improving access to breast and cervical cancer screening and follow-up.
Ragas DM; Nonzee NJ; Tom LS; Phisuthikul AM; Luu TH; Dong X; Simon MA
Womens Health Issues; 2014; 24(5):511-8. PubMed ID: 25213744
[TBL] [Abstract][Full Text] [Related]
19. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
20. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
Pericleous L; Amin M; Goeree R
J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
